AIP
EDIT icon

Almanack Investment Partners’s Editas Medicine EDIT Stock Holding History

Almanack Investment Partners’s Portfolio EDIT Stock Details EDIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-333
Closed -$4K – 448
2022
Q3 		$4K Buy
+333
New +$5.19K ﹤0.01% 612

Other funds holding EDIT

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Almanack Investment Partners's EDIT Position: Q4 2022 in Review

Almanack Investment Partners sold out of Editas Medicine (EDIT) in Q4 2022, closing a stake of 333 shares — an estimated $4K sold.

Almanack Investment Partners first reported a position in EDIT in Q3 2022 and held it in 1 quarter. The position peaked at $4K in Q3 2022. 250 funds tracked by Wall St. Rank hold EDIT as of Q4 2022.

  • Almanack Investment Partners reported no remaining Editas Medicine position as of Q4 2022 after selling out during the quarter.
  • Almanack Investment Partners sold 333 Editas Medicine shares in Q4 2022, an estimated $4K.
  • Almanack Investment Partners first reported a position in Editas Medicine in Q3 2022 and held it in 1 quarter.
  • Almanack Investment Partners's Editas Medicine position peaked at $4K in Q3 2022.
  • 250 funds tracked by Wall St. Rank held Editas Medicine as of Q4 2022.

Based on Almanack Investment Partners's 13F filing for Q4 2022, filed 9 Feb 2023.